About Wound Biologics
Mechanical, chemical, thermal, and radiogenic damages can cause cuts, tears, and punctures in the skin, blood vessels, nerves, muscles, internal organs, bones, and joints. Wounds are of two types: acute and chronic. The reparative process in acute wounds occurs at a predictable and expected rate leading to faster healing, while it fails to occur in a predictable amount of time in chronic wounds.
Biologic wound healing process helps re-establish the innate repair mechanisms and may involve the application of biological agents such as plant-derived active biomolecules having antimicrobial, antioxidant, and anti-inflammatory attributes. Biologic dressings prevent evaporative water loss, protein and electrolyte loss, heat loss, and wound contamination. Wound biologics such as granular wound beds permit autolytic debridement for the healing process.
Technavio’s analysts forecast the global wound biologics market to grow at a CAGR of 20.63% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global wound biologics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of:
Technavio Announces the Publication of its Research Report – Global Wound Biologics Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Wound Biologics Market: Acelity, Integra LifeSciences, Organogenesis and Smith & Nephew.
Other Prominent Vendors in the market are: Avita Medical, BioDlogics, ConvaTec, Cytori Therapeutics, Intercytex, MacroCure, Molyncke Health Care, Nuo Therapeutics, Osiris Therapeutics and Regenerys.
Commenting on the report, an analyst from Technavio’s team said: “The growth of this market is driven by the rising demand for various biologics in advanced wound care segment. Products such as allografts and autografts have high efficacy rates, and these are used for healing chronic wounds such as diabetic foot ulcers and venous ulcers. The availability of a broad range of approved skin substitutes such as grafts, tissue scaffolds, and cell-based therapies are expected to increase its demand from physicians and patients during the forecast period.”
According to the report, chronic wounds such as diabetic foot ulcers, leg ulcers, and pressure ulcers lead to complications such as infections, ulceration, and insufficient blood supply and take longer duration for wound healing. This increases the demand for advanced wound care products such as skin substitutes and growth factors to improve the healing process, resulting in greater sales of these products.
Further, the report states that most of the wound biologics available in the market are regenerative medicine- and tissue engineering-based products. Procedures based on these products are risky, increasing the need for clinical trials to prove their safety and efficacy. Lack of clinical data for safety and efficacy of these products also hinders their use by physicians and surgeons.
Acelity, Integra LifeSciences, Organogenesis, Smith & Nephew, Avita Medical, BioDlogics, ConvaTec, Cytori Therapeutics, Intercytex, MacroCure, Molyncke Health Care, Nuo Therapeutics, Osiris Therapeutics, Regenerys.